Skip to main content
SpringerLink
Log in

Malignant Germ Cell Tumours of the Ovary

  • Chapter
  • First Online:
Fundamentals in Gynaecologic Malignancy

  • 511 Accesses

Abstract

Ovarian germ cell cancers are considered to be the most chemo sensitive amongst all ovarian cancers and have got a very good prognosis. They constitute around 20–25% of ovarian neoplasms, however, barely around 5% of them are cancerous. Unlike epithelial ovarian cancers, they affect a younger demographic, with over 70% of cases occurring between the ages of 10 and 30 [1, 2]. It is a rarity to find women with this cancer after 40 years of age. Being chemo sensitive tumours and along with rapid progress in chemotherapy delivery there has been an exponential improvement in survival in this rare group of patients with survival as high as 100% for early stage and 75% for advanced disease [3]. In this chapter we aim at briefly describing the pathogenesis and treatment of this rare group of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol. 2000;95(1):128–33.

    CAS  Google Scholar 

  2. Royal College of Obstetricians and Gynaecologists. Management of female malignant ovarian germ cell tumours. Sci Impact Pap no 52; 2016. p. 1–10.

    Google Scholar 

  3. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25(20):2938–43.

    Article  CAS  Google Scholar 

  4. Looijenga LHJ, Zafarna G, Grygalewicz B, Summersgill B, et al. Role of gain of 12p in germ cell tumour development. APMIS. 2003;111(1):161–73.

    Article  Google Scholar 

  5. Chaganti RSK, Rodriguez E, Mathew S. Origin of adult male mediastinal germ-cell tumours. Lancet. 1994;343(8906):1130–2.

    Article  CAS  Google Scholar 

  6. Roth LM, Talerman A. Recent advances in the pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol. 2006;25(4):305–20.

    Article  Google Scholar 

  7. Cossu-Rocca P, Zhang S, Roth LM, Eble JN, Zheng W, Abdul Karim FW, et al. Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. Mod Pathol. 2006;19(4):611–5.

    Article  CAS  Google Scholar 

  8. Van Nieuwenhuysen E, Busschaert P, Neven P, Han SN, Moerman P, Liontos M, et al. The genetic landscape of 87 ovarian germ cell tumors. Gynecol Oncol. 2018;151(1):61–8.

    Article  Google Scholar 

  9. King ME, DiGiovanni LM, Yung J-F, Clarke-Pearson DL. Immature teratoma of the ovary grade 3, with karyotype analysis. Int J Gynecol Pathol. 1990;9(2):178–84.

    Article  CAS  Google Scholar 

  10. World Health Organization, International Agency for Research on Cancer (IARC), WHO Classification of Tumours Editorial Board. WHO classification of tumours: female genital tumours, vol. 4. 5th ed. Lyon: IARC; 2020.

    Google Scholar 

  11. Chen Y, Luo Y, Han C, Tian W, Yang W, Wang Y, et al. Ovarian dysgerminoma in pregnancy: a case report and literature review. Cancer Biol Ther. 2018;19(8):649–58.

    Article  Google Scholar 

  12. Michael KK, Wampler K, Underwood J, Hansen C. Ovarian dysgerminoma: a case study. J Diagn Med Sonogr. 2015;31(5):327–30.

    Article  Google Scholar 

  13. Zogbi L, Gonçalves CV, Tejada VF, Martins D, Karam F, Machado dos Santos S, et al. Treatment of bilateral ovarian dysgerminoma with 11-year follow-up: a case report. Ann Med Surg. 2018;33:50–2.

    Article  Google Scholar 

  14. Schellhas HF. Malignant potential of the dysgenetic gonad: Part I. Obstet Gynecol. 1974;44(2):298–309.

    CAS  Google Scholar 

  15. Schwartz PE, Morris JM. Serum lactic dehydrogenase: A tumor marker for dysgerminoma. Obstet Gynecol. 1988;72(3):511–5.

    CAS  Google Scholar 

  16. Trinh DT, Shibata K, Hirosawa T, Umezu T, Mizuno M, Kajiyama H, et al. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary. J Obstet Gynaecol Res. 2012;38(5):841–8.

    Article  CAS  Google Scholar 

  17. Rabban JT, Zaloudek CJ. A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours. Histopathology. 2013;62(1):71–88.

    Article  Google Scholar 

  18. Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075–85.

    Article  Google Scholar 

  19. Cao D, Guo S, Allan RW, Molberg KH, Peng Y. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol. 2009;33(6):894–904.

    Article  Google Scholar 

  20. Kaur B. Pathology of malignant ovarian germ cell tumours. Diagn Histopathol. 2020;26(6):289–97.

    Article  Google Scholar 

  21. Kurman RJ, Norris HJ. Embryonal carcinoma of the ovary. A clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer. 1976;38(6):2420–33.

    Article  CAS  Google Scholar 

  22. Lau SK, Weiss LM, Chu PG. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30. Mod Pathol. 2007;20(3):320–5.

    Article  CAS  Google Scholar 

  23. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer. 2004;101(9):2006–10.

    Article  Google Scholar 

  24. Rao KVLN, Konar S, Gangadharan J, Vikas V, Sampath S. A pure non-gestational ovarian choriocarcinoma with delayed solitary brain metastases: case report and review of the literature. J Neurosci Rural Pract. 2015;6(4):578–81.

    Article  Google Scholar 

  25. Goswami D, Sharma K, Zutshi V, Tempe A, Nigam S. Nongestational pure ovarian choriocarcinoma with contralateral teratoma. Gynecol Oncol. 2001;80(2):262–6.

    Article  CAS  Google Scholar 

  26. Tsujioka H, Hamada H, Miyakawa T, Hachisuga T, Kawarabayashi T. A pure nongestational choriocarcinoma of the ovary diagnosed with DNA polymorphism analysis. Gynecol Oncol. 2003;89(3):540–2.

    Article  Google Scholar 

  27. Takemori M, Nishimura R, Yamasaki M, Kawabe Y, Hasegawa K. Ovarian mixed germ cell tumor composed of polyembryoma and immature teratoma. Gynecol Oncol. 1998;69(3):260–3.

    Article  CAS  Google Scholar 

  28. Goyal LD, Kaur S, Kawatra K. Malignant mixed germ cell tumour of ovary—an unusual combination and review of literature. J Ovarian Res. 2014;7(1):1–4.

    Article  Google Scholar 

  29. Zamani N, Rezaei Poor M, Ghasemian Dizajmehr S, Alizadeh S, Modares GM. Fertility sparing surgery in malignant ovarian germ cell tumor (MOGCT): 15 years experiences. BMC Womens Health. 2021;21(1):1–7.

    Article  Google Scholar 

  30. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev. 2008;34:427–41.

    Article  CAS  Google Scholar 

  31. Rana AN, Humad H, Muhammad Asif A, Ghannam D, Nadeem N. Germ cell tumor presenting with precocious puberty in a girl in United Arab Emirates. Dubai Med J. 2020;3(1):32–6.

    Article  Google Scholar 

  32. Jorge S, Jones NL, Chen L, Hou JY, Tergas AI, Burke WM, et al. Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998–2012. Gynecol Oncol. 2016;142(2):261–6.

    Article  Google Scholar 

  33. Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary. A clinical and pathologic analysis of 71 cases. Cancer. 1976;38(6):2404–19.

    Article  CAS  Google Scholar 

  34. Jimerson GK, Woodruff JD. Ovarian extraembryonal teratoma. I. Endodermal sinus tumor. Am J Obstet Gynecol. 1977;127(1):73–9.

    Article  CAS  Google Scholar 

  35. Berek JS, HackerNF HT. Gynecologic Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2015. p. 518p.

    Google Scholar 

  36. Prat J, Belhadj H, Berek J, Bermudez A, Bhatla N, Cain J, et al. Figo’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87–9.

    Article  CAS  Google Scholar 

  37. Li J, Wu X. Current strategy for the treatment of ovarian germ cell tumors: role of extensive surgery. Curr Treat Options in Oncol. 2016;17(8):44.

    Article  Google Scholar 

  38. Billmire DF, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg. 2004;39(3):424–9.

    Article  CAS  Google Scholar 

  39. Qin B, Xu W, Li Y. Are omentectomy and lymphadenectomy necessary in patients with apparently early-stage malignant ovarian germ cell tumors? Int J Gynecol Cancer. 2019;29(2):398–403.

    Article  Google Scholar 

  40. Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer. 2011;105:493–7.

    Article  CAS  Google Scholar 

  41. Göbel U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D. Germ-cell tumors in childhood and adolescence. Ann Oncol. 2000;11(3):263–71.

    Article  Google Scholar 

  42. Baranzelli MC, Bouffet E, Quintana E, Portas M, Thyss A, Patte C. Non-seminomatous ovarian germ cell tumours in children. Eur J Cancer. 2000;36(3):376–83.

    Article  CAS  Google Scholar 

  43. Low JJH, Ilancheran A, Ng JS. Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):347–55.

    Article  Google Scholar 

  44. Low JJH, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors: a review of 74 cases. Cancer. 2000;89(2):391–8.

    Article  CAS  Google Scholar 

  45. Buttram VC, Vaquero C. Post-ovarian wedge resection adhesive disease. Fertil Steril. 1975;26(9):874–6.

    Article  Google Scholar 

  46. Schwartz PE, Chambers SK, Chambers JT, Kohorn E, McIntosh S. Ovarian germ cell malignancies: the Yale University experience. Gynecol Oncol. 1992;45(1):26–31.

    Article  CAS  Google Scholar 

  47. Gomes PJ, Rustin GJS. Attempted preservation of one gonad in patients with bilateral germ cell tumours. Clin Oncol. 1996;8(6):397–9.

    Article  CAS  Google Scholar 

  48. Zhao T, Liu Y, Jiang H, Zhang H, Lu Y. Management of bilateral malignant ovarian germ cell tumors: experience of a single institute. Mol Clin Oncol. 2016;5(2):383–7.

    Article  CAS  Google Scholar 

  49. Williams SD, Blessing JA, DiSaia PJ, Major FJ, Ball HG, Liao SY. Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience. Gynecol Oncol. 1994;52(3):287–91.

    Article  CAS  Google Scholar 

  50. Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the gynecologic oncology group. J Clin Oncol. 1994;12(4):701–6.

    Article  CAS  Google Scholar 

  51. Gershenson DM, Copeland LJ, Del Junco G, Edwards CL, Wharton JT, Rutledge FN. Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol. 1986;67(6):789–93.

    Article  CAS  Google Scholar 

  52. Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer. 1982;50(8):1629–35.

    Article  CAS  Google Scholar 

  53. Willis GW, Hajdu SI. Histologically benign teratoid metastasis of testicular embryonal carcinoma: report of five cases. Am J Clin Pathol. 1973;59(3):338–43.

    Article  CAS  Google Scholar 

  54. Merrin C, BaumBenigngartner G, Wajsman Z. Benign transformation of testicular carcinoma by chemotherapy. Lancet. 1975;305(7897):43–4.

    Article  Google Scholar 

  55. Amsalem H, Nadjari M, Prus D, Hiller N, Benshushan A. Growing teratoma syndrome vs. chemotherapeutic retroconversion: case report and review of the literature. Gynecol Oncol. 2004;92(1):357–60.

    Article  CAS  Google Scholar 

  56. Munkarah A, Gershenson DM, Levenback C, Silva EG, Messing MJ, Morris M, et al. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol. 1994;55(2):217–23.

    Article  CAS  Google Scholar 

  57. Rezk Y, Sheinfeld J, Chi DS. Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature. Gynecol Oncol. 2005;96(3):883–7.

    Article  Google Scholar 

  58. Wu X, Han LY, Xu X, Li Z. Recurrent immature teratoma of the ovary: a case report of radical secondary cytoreduction with replacement of the aortic bifurcation. Gynecol Oncol. 2004;95(3):746–9.

    Article  Google Scholar 

  59. Uccello M, Boussios S, Samartzis EP, Moschetta M. Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches. Ann Transl Med. 2020;8(24):1713.

    Article  Google Scholar 

  60. Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004;95(3):695–700.

    Article  CAS  Google Scholar 

  61. Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, Wit RD, De Mulder PH, Dearnaley DPCP. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and. J Clin Oncol. 1997;15(5):1844–52.

    Article  CAS  Google Scholar 

  62. Simone CG, Markham MJ, Dizon DS. Chemotherapy in ovarian germ cell tumors: a systematic review. Gynecol Oncol. 2016;141(3):602–7.

    Article  CAS  Google Scholar 

  63. Parkinson CA, Hatcher HM, Earl HM, Ajithkumar TV. Multidisciplinary management of malignant ovarian germ cell tumours. Gynecol Oncol. 2011;121(3):625–36.

    Article  CAS  Google Scholar 

  64. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16(7):2500–4.

    Article  CAS  Google Scholar 

  65. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559–63.

    Article  CAS  Google Scholar 

  66. Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJS, Cook PA, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005;93(2):178–84.

    Article  CAS  Google Scholar 

  67. Bower M, Newlands ES, Holden L, Rustin GJS, Begent RHJ. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997;8(5):477–83.

    Article  CAS  Google Scholar 

  68. Broun ER, Nichols CR, Gize G, Cornetta K, Hromas RA, Schacht B, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer. 1997;79(8):1605–10. [cited 2020 Nov 17]. Available from: https://pubmed.ncbi.nlm.nih.gov/19822531/

    Article  CAS  Google Scholar 

  69. De Giorgi U, Richard S, Badoglio M, Kanfer E, Bourrhis JH, Nicolas-Virelizier E, et al. Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2017;28(8):1910–6.

    Article  Google Scholar 

  70. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, et al. Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):140–6.

    Article  Google Scholar 

  71. Porcu P, Bhatia S, Sharma M, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol. 2000;18(6):1181–6.

    Article  CAS  Google Scholar 

  72. Kollmannsberger C, Honecker F, Bokemeyer C. Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother. 2008;9(13):2259–72.

    Article  CAS  Google Scholar 

  73. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: A study of the German Testicular Cancer Study Group. Ann Oncol. 2008;19(3):448–53.

    Article  CAS  Google Scholar 

  74. Lorch A, Neubauer A, Hackenthal M, Dieing A, Hartmann JT, Rick O, et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol. 2009;21(4):820–5.

    Article  Google Scholar 

  75. Guo H, Chen H, Wang W, Chen L. Clinicopathological features, prognostic factors, survival trends, and treatment of malignant ovarian germ cell tumors: A SEER Database Analysis. Oncol Res Treat. 2021;44(4):145–53.

    Article  Google Scholar 

  76. Meisel JL, Woo KM, Sudarsan N, Eng J, Patil S, Jacobsen EP, et al. Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecol Oncol. 2015;138(3):566.

    Article  Google Scholar 

  77. De La Motte RT, Pautier P, Rey A, Duvillard P, Kerbrat P, Troalen F, et al. Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. Eur J Cancer. 2011;47(2):175–82.

    Article  Google Scholar 

  78. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, et al. Prognostic factors in malignant ovarian germ cell tumours (the surveillance, epidemiology and end results experience 1978-2010). Eur J Cancer. 2014;50(11):1942–50.

    Article  CAS  Google Scholar 

  79. Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862–6.

    Article  Google Scholar 

  80. Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2792–7.

    Article  Google Scholar 

  81. Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol. 2006;103(3):1109–21.

    Article  Google Scholar 

  82. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(13):890–6.

    Article  Google Scholar 

  83. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994–2001. [cited 2022 Jan 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/29620997/

    Article  Google Scholar 

  84. Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568–74.

    Article  CAS  Google Scholar 

  85. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rørth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991;338(8763):359–63.

    Article  CAS  Google Scholar 

  86. Colombo N, Peiretti M, Castiglione M. Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):iv24–6.

    Article  Google Scholar 

  87. Behtash N, Zarchi MK. Dysgerminoma in three patients with Swyer syndrome. World J Surg Oncol. 2007;23(5):71.

    Article  Google Scholar 

  88. Bilen MA, Hariri H, Leon C, Guo CC, Kuban DA, Pisters LL, et al. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature. Clin Genitourin Cancer. 2014;12:e147–50.

    Article  Google Scholar 

  89. Salani R, Khanna N, Frimer M, Bristow RE, Chen L, may. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017;146(1):3–10. [cited 2022 Jan 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/28372871/

    Article  Google Scholar 

  90. NCCN.org. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) NCCN Guidelines for Patients® [cited 2022 Jan 27]; Available from: www.nccn.org/patients

Download references

Author information

Authors and Affiliations

  1. Department of Gynaecologic Oncology, Dr. Bhubaneswar Borooah Cancer Institute (A Unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Amal Chandra Kataki, Upasana Baruah & Munlima Hazarika

  2. Department of Gynaecological Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India

    Pallavi Ramachandra

Authors
  1. Amal Chandra Kataki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Upasana Baruah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Munlima Hazarika
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pallavi Ramachandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Gynaecologic Oncology, Dr Bhubaneswar Borooah Cancer Institute (A unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Amal Chandra Kataki

  2. Department of Gynaecologic Oncology, Dr Bhubaneswar Borooah Cancer Institute (A unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Debabrata Barmon

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kataki, A.C., Baruah, U., Hazarika, M., Ramachandra, P. (2022). Malignant Germ Cell Tumours of the Ovary. In: Kataki, A.C., Barmon, D. (eds) Fundamentals in Gynaecologic Malignancy. Springer, Singapore. https://doi.org/10.1007/978-981-19-5860-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5860-1_17

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5859-5

  • Online ISBN: 978-981-19-5860-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation